← Back to Screener
Immatics N.V. Ordinary Shares (IMTX)
Price$9.79
Value ScoreD
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-16.34%
Price vs S&P 500 (4W)-13.89%
VGM Score39.72
Market Capitalization$1.52B
P/E Ratio (Annual)79.47x
All Metrics
Book Value / Share (Quarterly)$3.86
P/TBV (Annual)2.53x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-34.63%
Cash Flow / Share (Quarterly)$-1.60
Price vs S&P 500 (YTD)-14.92%
Net Profit Margin (TTM)-574.86%
EPS (TTM)$-1.98
10-Day Avg Trading Volume0.71M
EPS Excl Extra (TTM)$-1.98
Revenue Growth (5Y)9.05%
EPS (Annual)$-1.86
ROI (Annual)-39.31%
Net Profit Margin (5Y Avg)-163.79%
Cash / Share (Quarterly)$3.84
Revenue Growth QoQ (YoY)-59.04%
P/E Normalized (Annual)79.47x
ROA (Last FY)-34.93%
Revenue Growth TTM (YoY)-74.13%
EBITD / Share (TTM)$-1.85
ROE (5Y Avg)-90.19%
Operating Margin (TTM)-570.30%
Cash Flow / Share (Annual)$-1.58
P/B Ratio2.50x
P/B Ratio (Quarterly)2.51x
Net Income / Employee (Annual)$-797,171
EV / Revenue (TTM)22.87x
Net Interest Coverage (TTM)-11.09x
ROA (TTM)-39.13%
EV / EBITDA (TTM)23.12x
EPS Incl Extra (Annual)$-1.86
Current Ratio (Annual)11.72x
Quick Ratio (Quarterly)8.61x
3-Month Avg Trading Volume0.50M
52-Week Price Return69.38%
EV / Free Cash Flow (Annual)8.67x
Revenue / Employee (TTM)$151,385
Tangible BV / Share (Quarterly)$3.84
P/S Ratio (Annual)23.60x
Asset Turnover (Annual)0.09x
52-Week High$12.41
Operating Margin (5Y Avg)-164.18%
EPS Excl Extra (Annual)$-1.86
CapEx CAGR (5Y)-1.93%
Tangible BV CAGR (5Y)41.06%
26-Week Price Return-8.42%
Quick Ratio (Annual)11.42x
13-Week Price Return-3.55%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)8.78x
Enterprise Value$986.49M
Revenue / Share Growth (5Y)-9.56%
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)21.07%
Revenue / Employee (Annual)$195,910
Pretax Margin (Annual)-411.13%
Cash / Share (Annual)$4.05
3-Month Return Std Dev49.90%
Net Income / Employee (TTM)$-870,030
ROE (Last FY)-40.58%
Net Interest Coverage (Annual)-3.31x
EPS Basic Excl Extra (Annual)$-1.86
P/FCF (TTM)16.33x
Receivables Turnover (TTM)7.65x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-1.98
Receivables Turnover (Annual)8.07x
ROI (TTM)-45.49%
P/S Ratio (TTM)30.55x
Pretax Margin (5Y Avg)-164.17%
Revenue / Share (Annual)$0.46
Tangible BV / Share (Annual)$4.16
Price vs S&P 500 (52W)45.01%
Year-to-Date Return-6.76%
5-Day Price Return-12.12%
EPS Normalized (Annual)$-1.86
ROA (5Y Avg)-19.11%
Net Profit Margin (Annual)-407.01%
Month-to-Date Return-14.94%
Cash Flow / Share (TTM)$-1.22
EBITD / Share (Annual)$-1.63
Operating Margin (Annual)-377.11%
LT Debt / Equity (Annual)5.82x
ROI (5Y Avg)-67.06%
LT Debt / Equity (Quarterly)6.45x
EPS Basic Excl Extra (TTM)$-1.98
P/TBV (Quarterly)2.52x
P/B Ratio (Annual)2.52x
Pretax Margin (TTM)-577.38%
Book Value / Share (Annual)$4.18
Price vs S&P 500 (13W)-11.80%
Beta1.33x
P/FCF (Annual)12.13x
Revenue / Share (TTM)$0.32
ROE (TTM)-47.09%
52-Week Low$5.05
vGradeD
gGradeD
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.50est. -0.47
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.35
4.35
4.33
4.33
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMTXImmatics N.V. Ordinary Shares | D | D | C | $9.79 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Immatics NV is a biotechnology company developing T-cell redirecting immunotherapies for cancer treatment. The company generates revenue primarily through strategic partnerships and collaboration agreements with pharmaceutical and biotechnology firms. The United States represents its largest revenue source.